Document is current

Article History

Received: 16 August 2024

Accepted: 6 September 2024

First Online: 13 September 2024

Declarations

:

: O.G. has no relevant financial or non-financial interests to disclose. M.P.M has received consulting Fees from Telix, Zap, Xoft, Kazia Therapeutics, Novocure; holds a Scientific Advisory Board role for Mevion; serves as the NRG Brain Tumor Committee Chair; Board of Directors, Xcision (unpaid); has Stock in Chimerix. R.K. has received honoraria from Elekta AB, Accuray Inc., Novocure Inc., ViewRay Inc., Elsevier Inc., Brainlab, Peerview Institute for Medical Education, and Ion Beam Applications; consulting fees from Kazia Therapeutics, Elekta AB, ViewRay Inc., Castle Biosciences, Novocure Inc.; institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, ViewRay Inc., Brainlab, Cantex Pharmaceuticals, Kazia Therapeutics and Ion Beam Applications; support for travel or meeting attendance by Elekta AB, Accuray Inc., Novocure Inc., Peerview Institute for Medical Education, Brainlab, ViewRay Inc.; and participated on an advisory board for Viewray Medical Advisory Board, GT Medical Technologies Data Safety Monitoring Board, Insightec Ltd, Plus Therapeutics Inc.